Activity Summary:
To further expand knowledge from the Talking HLH: Practical Insights for Diagnosing and Managing Adult HLH, presented by Drs. Sarah Nikiforow and Daniella Schwartz, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Adult HLH Diagnostic and Management Algorithm
A visually structured, step-by-step clinical algorithm outlining the recommended approach to evaluating and managing suspected adult HLH.

Adult HLH Recognition and Diagnostic Quick-Reference Guide
A concise clinical reference tool summarizing early warning signs, key laboratory markers, and recommended first-line investigations for suspected adult HLH.

Clinical Slide Kit
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Guideline & References
Links to key clinical guidelines, landmark publications, diagnostic frameworks, and educational resources related to adult HLH and hyperinflammatory syndromes

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early diagnosis and management remain challenging in clinical practice. Because many adults present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, timely recognition and treatment can be difficult.

This four-episode podcast series explores the full spectrum of adult HLH, from raising diagnostic suspicion to implementing contemporary treatment strategies. Through expert discussion and real-world clinical insights, Dr. Sarah Nikiforow and Dr. Daniella Schwartz aim to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
Adult HLH is increasingly recognized as part of a broader hyperinflammatory spectrum, yet early identification and management remain challenging in routine clinical practice. Many adult patients present with nonspecific symptoms that overlap with sepsis, malignancy-associated inflammation, or autoimmune disease, which can delay recognition and treatment.

In this series, Drs. Sarah Nikiforow and Daniella Schwartz explore the full spectrum of adult HLH, from diagnostic suspicion to modern treatment approaches. Through four episodes, this activity aims to strengthen the ability to recognize HLH across diverse clinical settings, integrate biomarkers and prognostic indicators into clinical decision-making, and apply adult-specific management strategies, including emerging therapeutic options.

Activity Summary:
To further expand knowledge from the Relapsed/Refractory Multiple Myeloma in Real Time: Practical Insights for the First Relapse, presented by Drs. Ajai Chari and Sagar Lonial, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Clinical Slide Kit
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcripts
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Reference and Resources
Direct access to featured studies, abstracts, and other kit materials cited in the program.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Activity Summary:
Relapsed/refractory multiple myeloma (RRMM) remains a complex and rapidly evolving disease state, particularly at first relapse, when timely, evidence-based decisions regarding risk stratification, treatment selection, and sequencing are essential. Healthcare professionals often face challenges keeping pace with expanding therapeutic options, emerging immunotherapies, and evolving clinical guidelines.

Many clinicians report uncertainty in differentiating mechanisms of action, managing immune-related toxicities, and optimizing treatment sequencing in the setting of emerging resistance. In addition, community and mixed-practice settings may encounter practical barriers, including staffing constraints, infusion capacity limitations, and workflow integration challenges. This mini-module series features expert-led discussions focused on practical implementation strategies to support confident, guideline-aligned decision-making and effective real-world application in RRMM care.

Activity Summary:
To reinforce key insights and facilitate post-activity implementation, participants can download, on-demand resources designed to support ongoing clinical decision-making. These concise, easy-to-reference tools translate emerging evidence into practical strategies that clinicians can reference when integrating today’s most effective therapeutic approaches.

Clinical Slide Deck:
A curated set of high-yield, evidence-based slides including data visuals, algorithms, and expert insights.

Expert Commentary Transcripts:
A downloadable transcript of the podcast/video for learners who prefer a text-based review.

Strengthen your knowledge. Support your practice. Improve patient care.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:

CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.

In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.

Activity Summary:

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.

Activity Summary:
These clinical videos and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at the annual hematology meeting December 6-9 in Orlando, FL. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights covers leukemia, myelodysplastic syndromes (MDS), myelofibrosis (MF), as well as hemophilia A and B. Please click the links to participate in each of these activities.

Activity Summary:
A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Enhance your learning from the Hematologic Cancer Updates activity with a curated resource library built for real-world clinical needs. Access downloadable visual summaries, practical takeaways and ready-to-share content—ideal for quick reference and team-based discussions, and perfectly aligned with the podcast and highlights video.

Clinical Slide Deck: Downloadable PDF of presentation slides, including data visuals, algorithms and expert insights—ideal for review, teaching or clinical discussions.

Clinical Snippet Highlights: Concise, one-page summaries of key posters and abstracts, offering quick, actionable insights to support day-to-day clinical decision-making.

Expert Commentary Transcript: A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS), and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Activity Summary:
Novel therapies and combinations are currently under investigation for the treatment of acute myeloid leukemia (AML). These include venetoclax, FLT3 inhibitors, IDH inhibitors, menin inhibitors, antibody-drug conjugates, CAR T-cell approaches, and novel targeted agents. Similarly, a number of clinical trials are underway for other leukemias, myelodysplastic syndromes (MDS), and myelofibrosis (MF).

In this Conference Highlights accredited video, Dr. Raajit Rampal discusses the latest cutting-edge evidence in leukemia, MDS and MF, presented in Orlando, FL December 6th – 9th, integrating new evidence into personalized approaches, optimizing patient outcomes, and improving the overall quality of care.

Activity Summary:
This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.

Activity Summary:
This video Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:
Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Drs C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this lecture library, Dr. Cindy Neunert provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
Stroke prevention continues to challenge clinicians, especially when balancing effective anticoagulation with the risks of bleeding. During this video series, Drs C. Michael Gibson and Manesh Patel provide rapid updates on the latest science shaping stroke prevention. Each 10–15-minute episode delivers digestible insights on topics such as emerging anticoagulation strategies, residual stroke risk, and clinical trial takeaways. This series is perfect for time-pressed healthcare professionals as it offers actionable knowledge designed to support evidence-based decision-making.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this podcast, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:
There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In these mini-module episodes, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:

Patients with interferon gamma (IFN–γ) driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway and, innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs to improve outcomes among patients.

Activity Summary:
What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Activity Summary:
This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Activity Summary:

There have been multiple key advances in the treatment landscape of chronic lymphocytic leukemia (CLL) in 2024. To that end, a number of double and triple combination studies have been completed or are currently underway, and innovative therapies such as bispecific antibodies and chimeric antigen receptor (CAR) T cells are being developed for CLL. In Highlights and Hindsight in CLL, Dr. Matthew Davids describes the most significant ongoing studies and publications in CLL from 2024 and details their impact on the treatment continuum. This activity enables participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.